Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04412629 · ClinicalTrials.gov registry record · Phase 2
Cabozantinib in High Grade Neuroendocrine Neoplasms
A Phase 2 study of High Grade Neuroendocrine Neoplasms, sponsored by Washington University School of Medicine.
- Active
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
- 1
- Study location
NCT04412629 is a Phase 2 study of High Grade Neuroendocrine Neoplasms that is active but no longer recruiting, run by Washington University School of Medicine. The registered enrollment target is 35 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04412629, a Phase 2 study of High Grade Neuroendocrine Neoplasms, is active but no longer recruiting, sponsored by Washington University School of Medicine.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
- 1
- Study location
Study Summary
High grade neuroendocrine neoplasm patients are treated with platinum doublets such as carboplatin and etoposide mimicking the current guidelines for small cell lung cancer (SCLC). Unfortunately, recurrences are common and most patients with metastatic disease succumb to it within a year. There is no extensive literature or consensus on second- or third-line options (which include FOLFOX, FOLFIRI, capecitabine and temozolomide, taxanes or immunotherapy) and there is urgent need for better regimens.
Conditions Studied
Interventions
- DRUG Cabozantinib
- PROCEDURE Blood for plasma biomarkers
- PROCEDURE Tissue biopsy
Study Locations (1)
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2020-11-24 |
| Est. Completion | 2026-09-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04412629
The ClinicalTrials.gov registry entry for NCT04412629 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with High Grade Neuroendocrine Neoplasms appearing as the primary indexed condition, and to 3 interventions - of which Cabozantinib is the first listed.
NCT04412629 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT04412629 about?
NCT04412629 is a clinical study titled "Cabozantinib in High Grade Neuroendocrine Neoplasms". High grade neuroendocrine neoplasm patients are treated with platinum doublets such as carboplatin and etoposide mimicking the current guidelines for small cell lung cancer (SCLC). Unfortunately, recurrences are common and most patients with metastatic disease succumb to it within a year. There is n...
What is the current status of trial NCT04412629?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2020-11-24. Estimated completion is 2026-09-30.
What conditions does trial NCT04412629 study?
This clinical trial studies the following conditions: High Grade Neuroendocrine Neoplasms.
What interventions are being tested in trial NCT04412629?
The interventions under investigation include: Cabozantinib (DRUG), Blood for plasma biomarkers (PROCEDURE), Tissue biopsy (PROCEDURE).
Who is sponsoring clinical trial NCT04412629?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04412629 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for High Grade Neuroendocrine Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.